Clinical research runs on numbers, but some of the most important ones are moving faster than trial teams and systems can usually keep up. By 2032, the global CRO market is projected to reach $101.3 billion, while ClinicalTrials.gov already indexed 410,000+ studies and contained 214,000+ interventional studies as of March 2024. In this post, we connect market growth, trial operations, and regulatory timelines to show where speed improves and where delays keep showing up.
Key Takeaways
- The global CRO market is projected to reach $101.3 billion by 2032
- The global eClinical solutions market is projected to reach $44.1 billion by 2032
- The global SMO market is projected to reach $10.1 billion by 2030
- In 2022, 6,957 sites were listed in the Drug Trials Snapshots database for industry-sponsored trials in the U.S.
- Between 2006 and 2019, the number of clinical trial sites in the U.S. reporting to ClinicalTrials.gov increased by 12.7% (site counts per year)
- In 2022, 55% of clinical trial sites in the U.S. had fewer than 5 active industry-sponsored interventional trials at a time
- In 2021, sponsors reported using remote eConsent for 41% of trials that adopted decentralized models
- In 2022, 45% of sites reported having access to trial participant recruitment tools integrated with EHR systems
- In 2020, median enrollment speed for oncology trials was 2.2 patients per month (from submission-to-completion dataset analysis)
- For industry-sponsored interventional trials registered on ClinicalTrials.gov (2015–2019), median recruitment time was 6.8 months
- Across 2014–2017, mean protocol amendments per trial were 2.3, contributing to delays
- ClinicalTrials.gov reported 410,000+ studies (all types) indexed as of 2024-03 (studies count on registry)
- As of 2024-03, ClinicalTrials.gov contained 214,000+ interventional studies
- The proportion of trials on ClinicalTrials.gov with results posted increased from 39% to 58% between 2012 and 2020 (results posting trend)
Clinical trial operations are scaling fast, but recruitment and data integrity remain key bottlenecks.
Related reading
01 · Category
Market Size5 stats
01
The global CRO market is projected to reach $101.3 billion by 2032[1]
02
The global eClinical solutions market is projected to reach $44.1 billion by 2032[1]
03
The global SMO market is projected to reach $10.1 billion by 2030[1]
04
The global clinical trial recruitment services market is projected to reach $5.1 billion by 2030[2]
05
FDA received 874,075 investigational new drug (IND) submissions from 2004–2021 (annual totals varied by year)[3]
Interpretation
Market Size Interpretation
From a market size perspective, the clinical research ecosystem is expanding quickly with the CRO segment projected to grow to $101.3 billion by 2032 and eClinical solutions to $44.1 billion by 2032, underscoring rising investment and demand across trial execution and supporting technologies alongside steady FDA activity with 874,075 IND submissions from 2004 to 2021.
02 · Category
Workforce & Sites3 stats
01
In 2022, 6,957 sites were listed in the Drug Trials Snapshots database for industry-sponsored trials in the U.S.[4]
02
Between 2006 and 2019, the number of clinical trial sites in the U.S. reporting to ClinicalTrials.gov increased by 12.7% (site counts per year)[4]
03
In 2022, 55% of clinical trial sites in the U.S. had fewer than 5 active industry-sponsored interventional trials at a time[4]
Interpretation
Workforce & Sites Interpretation
From a Workforce and Sites perspective, the U.S. saw clinical trial site participation grow 12.7% from 2006 to 2019, yet in 2022 55% of industry sponsored sites had fewer than 5 active interventional trials at once, even with 6,957 sites listed overall.
03 · Category
Technology Adoption2 stats
Interpretation
Technology Adoption Interpretation
From a technology adoption standpoint, the steady rise in enabling digital capabilities is clear as remote eConsent reached 41% of decentralized trials in 2021 and by 2022 45% of sites had EHR integrated recruitment tools.
More related reading
04 · Category
Recruitment & Timing4 stats
01
In 2020, median enrollment speed for oncology trials was 2.2 patients per month (from submission-to-completion dataset analysis)[5]
02
For industry-sponsored interventional trials registered on ClinicalTrials.gov (2015–2019), median recruitment time was 6.8 months[6]
03
Across 2014–2017, mean protocol amendments per trial were 2.3, contributing to delays[7]
04
In a sample of 1,000 trials, median start-up delay (first posted to first enrollment) was 6 months[8]
Interpretation
Recruitment & Timing Interpretation
From a recruitment and timing perspective, trials are typically far from immediate, with median start-up delays of 6 months in a 1,000-trial sample and a median 6.8-month recruitment time for industry-sponsored interventional studies, while oncology enrollment proceeds at 2.2 patients per month and protocol amendments averaging 2.3 per trial across 2014 to 2017 help explain why timing often slips.
05 · Category
Regulatory & Evidence7 stats
01
ClinicalTrials.gov reported 410,000+ studies (all types) indexed as of 2024-03 (studies count on registry)[9]
02
As of 2024-03, ClinicalTrials.gov contained 214,000+ interventional studies[9]
03
The proportion of trials on ClinicalTrials.gov with results posted increased from 39% to 58% between 2012 and 2020 (results posting trend)[7]
04
FDA reported a median review time of 8.9 months for priority review for oncology in FY 2023[3]
05
FDA reported 55% of novel drug approvals in 2023 used accelerated approval pathway (share of novel drugs)[3]
06
FDA’s 21st Century Cures Act (RTOR) led to publication of 4,000+ structured template data elements by 2023 (structured data implementation outputs)[3]
07
In 2023, the number of FDA inspection findings tied to data integrity issues was 1,200+ (data integrity-related observations)[3]
Interpretation
Regulatory & Evidence Interpretation
Across Regulatory & Evidence, the push for stronger evidentiary standards is clear as ClinicalTrials.gov results posting rose from 39% to 58% between 2012 and 2020, while FDA continued to accelerate impact with 55% of 2023 novel drug approvals using the accelerated approval pathway.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priyanka Sharma. (2026, February 13). Clinical Research Statistics. Gitnux. https://gitnux.org/clinical-research-statistics
MLA
Priyanka Sharma. "Clinical Research Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-research-statistics.
Chicago
Priyanka Sharma. 2026. "Clinical Research Statistics." Gitnux. https://gitnux.org/clinical-research-statistics.
Sources & references
9 sources cited across this report